Becker Muscular Dystrophy (BMD)

Overview

Plain-Language Overview

Becker Muscular Dystrophy (BMD) is a genetic disorder that primarily affects the muscles, causing them to become weak and less functional over time. It is a condition that mainly involves the skeletal muscles, which are responsible for movement, and can also affect the heart muscle. People with BMD often experience difficulty walking, muscle cramps, and fatigue. The disease usually starts in childhood or adolescence but progresses more slowly than similar conditions. It is caused by changes in a gene that affects a protein important for muscle strength and stability. Over time, muscle weakness can impact daily activities and overall health.

Clinical Definition

Becker Muscular Dystrophy (BMD) is an X-linked recessive muscle disorder characterized by mutations in the DMD gene leading to reduced or abnormal dystrophin protein production. This protein is essential for maintaining the structural integrity of muscle fibers during contraction. Unlike Duchenne muscular dystrophy, BMD typically presents with a later onset and slower progression due to partially functional dystrophin. The disease primarily affects proximal muscles of the pelvic and shoulder girdles, causing progressive muscle weakness and wasting. Cardiac involvement, including dilated cardiomyopathy, is a major cause of morbidity. Diagnosis is important for genetic counseling and management of complications.

Inciting Event

There is no specific external trigger; disease onset is due to inherited mutations in the DMD gene.
Progressive muscle damage begins insidiously as dystrophin deficiency impairs muscle fiber stability.

Latency Period

Symptoms typically develop gradually over years to decades after birth.
Muscle weakness often becomes apparent in late childhood or adolescence.
Diagnosis is often delayed due to slow progression and mild early symptoms.

Diagnostic Delay

Mild or slowly progressive symptoms lead to misattribution to benign muscle fatigue or growth-related weakness.
Lack of awareness of Becker muscular dystrophy in late-onset muscle weakness delays diagnosis.
Normal early developmental milestones and absence of severe symptoms reduce clinical suspicion.
Misdiagnosis as other neuromuscular disorders or orthopedic conditions is common.

Clinical Presentation

Signs & Symptoms

Progressive proximal muscle weakness usually presenting in adolescence or early adulthood
Exercise intolerance and muscle cramps
Fatigue during physical activity
Delayed motor milestones may be present but less severe than Duchenne muscular dystrophy
Cardiac symptoms such as palpitations or exertional dyspnea in advanced cases

History of Present Illness

Gradual onset of proximal muscle weakness, especially in the pelvic and shoulder girdle muscles.
Difficulty with activities such as running, climbing stairs, and rising from the floor.
Muscle cramps and fatigue may be reported but are less prominent than weakness.
Calf muscle hypertrophy is often noted despite underlying muscle degeneration.
Symptoms progress slowly, with many patients remaining ambulatory into adulthood.

Past Medical History

Elevated serum creatine kinase levels may have been noted incidentally or during evaluation for muscle symptoms.
No history of acute muscle injury or inflammatory myopathy.
Absence of significant cardiac or respiratory symptoms early in disease course, though these may develop later.

Family History

X-linked inheritance pattern with affected male relatives such as maternal uncles or cousins.
Female relatives may be asymptomatic carriers with elevated creatine kinase or mild symptoms.
Family history of muscular dystrophy or unexplained muscle weakness supports diagnosis.

Physical Exam Findings

Calf pseudohypertrophy due to fatty infiltration and fibrosis of muscle tissue
Proximal muscle weakness, especially in the pelvic and shoulder girdle muscles
Gower sign positive indicating proximal lower limb weakness
Decreased deep tendon reflexes in affected muscles
Mild to moderate muscle atrophy in later stages

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Becker muscular dystrophy is established by identifying muscle weakness with a characteristic pattern on clinical exam and elevated serum creatine kinase (CK) levels. Confirmation requires genetic testing demonstrating mutations in the DMD gene that produce abnormal but partially functional dystrophin. Muscle biopsy may show reduced dystrophin on immunohistochemistry and dystrophic changes. Cardiac evaluation is also recommended due to common cardiomyopathy. Family history and X-linked inheritance pattern support the diagnosis.

Pathophysiology

Key Mechanisms

Mutations in the DMD gene cause reduced or abnormal dystrophin protein production, leading to muscle fiber fragility and progressive degeneration.
Partial preservation of dystrophin allows for a milder phenotype compared to Duchenne muscular dystrophy.
Loss of sarcolemmal integrity results in increased calcium influx and activation of proteases causing muscle cell damage.
Chronic muscle damage triggers fibrosis and fatty replacement of muscle tissue, impairing function.
Impaired muscle regeneration due to satellite cell exhaustion contributes to progressive weakness.

Involvement	Details
Organs	Skeletal muscles are primarily involved causing progressive proximal muscle weakness and calf hypertrophy.
Organs	Heart is commonly affected with dilated cardiomyopathy and arrhythmias in Becker muscular dystrophy.
Tissues	Skeletal muscle tissue undergoes progressive fibrosis and fatty replacement leading to weakness and wasting.
Tissues	Cardiac muscle tissue is affected by fibrosis and dilated cardiomyopathy contributing to morbidity.
Cells	Skeletal muscle fibers are the primary affected cells undergoing progressive degeneration due to defective dystrophin protein.
Cells	Cardiomyocytes are involved in the development of dilated cardiomyopathy seen in Becker muscular dystrophy.
Chemical Mediators	Creatine kinase is elevated in serum as a marker of ongoing muscle damage in Becker muscular dystrophy.
Chemical Mediators	Dystrophin deficiency due to mutations in the DMD gene leads to muscle fiber fragility and degeneration.

Treatments

Pharmacological Treatments

Corticosteroids (e.g., prednisone, deflazacort)
- Mechanism:
  - Reduce muscle inflammation and slow muscle degeneration by modulating immune response and stabilizing muscle cell membranes.
- Side effects:
  - Weight gain
  - Osteoporosis
  - Hypertension
  - Glucose intolerance
- Clinical role:
  - First-line
ACE inhibitors
- Mechanism:
  - Prevent or delay cardiomyopathy progression by reducing cardiac afterload and fibrosis.
- Side effects:
  - Hypotension
  - Hyperkalemia
  - Cough
- Clinical role:
  - Adjunctive
Beta blockers
- Mechanism:
  - Reduce cardiac workload and arrhythmia risk in cardiomyopathy associated with BMD.
- Side effects:
  - Bradycardia
  - Fatigue
  - Bronchospasm
- Clinical role:
  - Adjunctive

Non-pharmacological Treatments

Regular physical therapy to maintain muscle strength and prevent contractures.
Use of assistive devices such as braces or wheelchairs to improve mobility and prevent falls.
Cardiac monitoring with echocardiography and electrocardiogram to detect early cardiomyopathy.
Respiratory support including non-invasive ventilation in cases of respiratory muscle weakness.

Prevention

Pharmacological Prevention

Corticosteroids such as prednisone to slow muscle degeneration
ACE inhibitors or beta-blockers to prevent or manage cardiomyopathy
Anticoagulants may be used if immobilization increases thrombosis risk

Non-pharmacological Prevention

Regular physical therapy to maintain muscle strength and prevent contractures
Cardiac monitoring with echocardiography and ECG for early detection of cardiomyopathy
Respiratory function testing to monitor for decline and initiate support
Orthotic devices to improve mobility and prevent deformities
Genetic counseling for affected families

Outcome & Complications

Complications

Heart failure due to progressive cardiomyopathy
Respiratory failure from weakened respiratory muscles
Severe contractures limiting mobility
Increased risk of falls and fractures due to muscle weakness

Short-term Sequelae	Long-term Sequelae
Exercise-induced muscle pain and fatigue Transient muscle cramps Mild functional decline during periods of illness or inactivity	Progressive loss of ambulation often occurring in adulthood Chronic cardiomyopathy leading to heart failure Permanent joint contractures and scoliosis Chronic respiratory insufficiency requiring ventilatory support

Differential Diagnoses

Becker Muscular Dystrophy (BMD) versus Duchenne Muscular Dystrophy (DMD)

Becker Muscular Dystrophy (BMD)	Duchenne Muscular Dystrophy (DMD)
Later childhood onset (adolescence to early adulthood)	Early childhood onset (before 5 years)
Slower progression with ambulation often preserved into adulthood	Rapidly progressive weakness leading to loss of ambulation by early teens
Reduced or abnormal dystrophin expression on muscle biopsy or genetic testing	Absent dystrophin on muscle biopsy or genetic testing

Becker Muscular Dystrophy (BMD) versus Limb-Girdle Muscular Dystrophy (LGMD)

Becker Muscular Dystrophy (BMD)	Limb-Girdle Muscular Dystrophy (LGMD)
X-linked recessive inheritance	Autosomal recessive inheritance most common
Proximal weakness with characteristic calf hypertrophy	Predominant proximal limb-girdle weakness without calf hypertrophy
*Mutations in the DMD* gene affecting dystrophin**	Mutations in various sarcoglycan or other muscle proteins

Becker Muscular Dystrophy (BMD) versus Myotonic Dystrophy

Becker Muscular Dystrophy (BMD)	Myotonic Dystrophy
No myotonia	Myotonia (delayed muscle relaxation) present
Primarily skeletal muscle involvement without systemic features	Multisystem features including cataracts, cardiac conduction defects, and endocrine abnormalities
*Mutations or deletions in DMD* gene**	*CTG trinucleotide repeat expansion in DMPK* gene**

Becker Muscular Dystrophy (BMD) versus Inflammatory Myopathies (e.g., Polymyositis)

Becker Muscular Dystrophy (BMD)	Inflammatory Myopathies (e.g., Polymyositis)
Chronic progressive painless weakness	Subacute onset with muscle pain and weakness
Elevated creatine kinase without systemic inflammation or autoantibodies	Elevated creatine kinase with inflammatory markers and autoantibodies
No significant response to immunosuppressive therapy	Improvement with immunosuppressive therapy

Becker Muscular Dystrophy (BMD) versus Facioscapulohumeral Muscular Dystrophy (FSHD)

Becker Muscular Dystrophy (BMD)	Facioscapulohumeral Muscular Dystrophy (FSHD)
Proximal limb and calf muscle weakness predominates	Facial and scapular muscle weakness predominates
Adolescence to early adulthood with limb-girdle weakness	Typically adolescence or early adulthood with facial weakness
*Mutations or deletions in DMD* gene**	Deletion of D4Z4 repeat on chromosome 4q35